On June 19, 2026, Ultragenyx Pharmaceutical Inc. announced the issuance of 44,409 restricted stock units of their common stock to 15 recently recruited non-executive officers. The awards were given under the Ultragenyx Employment Inducement Plan, approved by the board of directors' compensation committee. These stocks were granted on June 16, 2026, as a crucial inducement for the new employees joining Ultragenyx, following Nasdaq Listing Rule 5635(c)(4). Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company concentrating on creating and marketing innovative treatments for rare and ultra-rare diseases.